Physician profile
Stella Tu
NPI 1639767940
$1,850.75
in general payments reported to CMS, 2019-2025
14 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $59.71 · 2023: $106 · 2024: $484 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,607.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $708.93 | 2024-2025 | Miebo, Xiidra, Sofport Ao |
| Dompe US, INC. | $251.17 | 2021-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $151.00 | 2022-2025 | Cequa |
| Ivantis, INC | $135.39 | 2021 | |
| Glaukos Corporation | $132.34 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Astellas Pharma Global Development | $131.12 | 2025 | Izervay |
| Thea Pharma INC. | $79.66 | 2024-2025 | Iyuzeh |
| Alcon Vision LLC | $72.95 | 2025 | Rocklatan, Eysuvis |
| Amgen INC. | $65.19 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $31.09 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $27.29 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $25.73 | 2025 | Vevye |
| Abbvie INC. | $20.23 | 2023 | Vuity, Lumigan, Alphagan P |
| Sight Sciences, INC. | $18.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Tu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.